Lonidamine plus adriamycin versus adriamycin alone in the adjuvant treatment of recurrent papillary carcinomas of the urinary bladder.
This paper reports the interim results of 25 patients included in a double-blind study in which the combination of Lonidamine plus adriamycin is compared to adriamycin alone in the adjuvant treatment of papillary carcinomas of the urinary bladder. Although it is impossible to draw any conclusion at this time on the therapeutic activity of this combination, tolerance was judged satisfactory.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use*; D005123:Eye / Q000187:drug effects; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D007191:Indazoles; D011720:Pyrazoles; D004317:Doxorubicin; C016371:lonidamine